PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
and after surgery in cisplatin-eligible patients with muscle-invasive bladder cancer Positive EV-304 data, combined with the recent unprecedented results from the EV-303 trial, highlight the potential of this combination to become a new platinum-free standard of care in an earlier stage of bladder cancer Results from the Phase 3 EV-304 trial will be presented at an upcoming medical meeting and discussed with global health authorities for potential regulatory filings TOKYO and NEW YORK Dec. 17, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor. This pivotal study is evaluating the combination as neoadjuvant and adjuvant treatment (bef
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer (NYSE:PFE) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Pfizer (NYSE:PFE) was given a new $24.00 price target on by analysts at Wolfe Research. They now have an "underperform" rating on the stock.MarketBeat
- PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin EligibilityPR Newswire
- FDA approves label change for Depo-Provera, adding brain tumor warning [MSNBC.com]MSNBC.com
- Pfizer (PFE): Reassessing Valuation After Cautious 2026 Outlook and Fading COVID-19 Revenue [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 11/4/25 - Beat
PFE
Sec Filings
- 12/16/25 - Form 8-K
- 12/2/25 - Form 4
- 11/21/25 - Form 8-K
- PFE's page on the SEC website